1. Morgan IG, Ohno-Matsui K, Saw S-M. Myopia. The Lancet. 2012;379(9827):1739–48.
2. Vitale S, Sperduto RD, Ferris FL. Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol. 2009;127(12):1632–9.
3. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036–42.
4. Vestergaard AH. Past and present of corneal refractive surgery: a retrospective study of long-term results after photorefractive keratectomy and a prospective study of refractive lenticule extraction. Acta Ophthalmol (Copenh). 2014 Mar;92 Thesis 2:1–21.
5. Marques EF, Leite EB, Cunha-Vaz JG. Corticosteroids for reversal of myopic regression after photorefractive keratectomy. J Refract Surg Thorofare NJ 1995. 1995 Jun;11(3 Suppl):S302-308.
6. Marcus MW, de Vries MM, Junoy Montolio FG, Jansonius NM. Myopia as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. Ophthalmology. 2011 Oct;118(10):1989-1994.e2.
7. Lee H, Roberts CJ, Kim T-I, Ambrósio R, Elsheikh A, Yong Kang DS. Changes in biomechanically corrected intraocular pressure and dynamic corneal response parameters before and after transepithelial photorefractive keratectomy and femtosecond laser-assisted laser in situ keratomileusis. J Cataract Refract Surg. 2017;43(12):1495–503.
8. Hugo J, Granget E, Ho Wang Yin G, Sampo M, Hoffart L. Intraocular pressure measurements and corneal biomechanical properties using a dynamic Scheimpflug analyzer, after several keratoplasty techniques, versus normal eyes. J Fr Ophtalmol. 2018 Jan;41(1):30–8.
9. Schallhorn JM, Schallhorn SC, Ou Y. Factors that influence intraocular pressure changes after myopic and hyperopic LASIK and photorefractive keratectomy: a large population study. Ophthalmology. 2015 Mar;122(3):471–9.
10. Shousha SM, Steit MAA, Hosny MH, Ewais WA, Shalaby AM. Comparison of different intraocular pressure measurement techniques in normal eyes, post surface and post lamellar refractive surgery. Clin Ophthalmol Auckl NZ. 2013;7:71.
11. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol Chic Ill 1960. 1963 Oct;70:492–9.
12. Javadi M-A, Mirbabaei-Ghafghazi F, Mirzade M, Yazdani S, Yaseri M. Steroid induced ocular hypertension following myopic photorefractive keratectomy. J Ophthalmic Vis Res. 2008;3(1):42.
13. Yamamoto Y, Komatsu T, Koura Y, Nishino K, Fukushima A, Ueno H. Intraocular pressure elevation after intravitreal or posterior sub-Tenon triamcinolone acetonide injection. Can J Ophthalmol. 2008;43(1):42–7.
14. Busool Y, Mimouni M, Vainer I, Levartovsky S, Sela T, Munzer G, et al. Risk factors predicting steroid-induced ocular hypertension after photorefractive keratectomy. J Cataract Refract Surg. 2017;43(3):389–93.
15. Lau L-I, Chen K-C, Lee F-L, Chen S-J, Ko Y-C, Liu CJ-L, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection in a Chinese population. Am J Ophthalmol. 2008;146(4):573–8.
16. Lam DSC, Fan DSP, Ng JSK, Yu CBO, Wong CY, Cheung AYK. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Experiment Ophthalmol. 2005 Jun;33(3):252–8.
17. Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet Lond Engl. 1997 Oct 4;350(9083):979–82.
18. Friedman DS, Holbrook JT, Ansari H, Alexander J, Burke A, Reed SB, et al. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology. 2013 Aug;120(8):1571–9.
19. Parekh A, Srivastava S, Bena J, Albini T, Nguyen QD, Goldstein DA. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant. JAMA Ophthalmol. 2015 May;133(5):568–73.
20. Leske MC, Connell AM, Wu SY, Hyman LG, Schachat AP. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol Chic Ill 1960. 1995 Jul;113(7):918–24.
21. Chihara E, Liu X, Dong J, Takashima Y, Akimoto M, Hangai M, et al. Severe myopia as a risk factor for progressive visual field loss in primary open-angle glaucoma. Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd. 1997;211(2):66–71.
22. Mitchell P, Hourihan F, Sandbach J, Wang JJ. The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology. 1999 Oct;106(10):2010–5.
23. Xu L, Wang Y, Wang S, Wang Y, Jonas JB. High myopia and glaucoma susceptibility the Beijing Eye Study. Ophthalmology. 2007 Feb;114(2):216–20.
24. Chang DF, Tan JJ, Tripodis Y. Risk factors for steroid response among cataract patients. J Cataract Refract Surg. 2011;37(4):675–81.
25. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714–20.
26. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48–56.
27. Kanellopoulos AJ, Cruz EM, Ang RET, Asimellis G. Higher incidence of steroid-induced ocular hypertension in keratoconus. Eye Vis. 2016;3(1):4.
28. Rhee DJ, Peck RE, Belmont J, Martidis A, Liu M, Chang J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol. 2006;90(8):999–1003.
29. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138(5):740–3.